NCT00136591 - A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Follicular Lymphoma

Interventions

DRUG

Bortezomib

Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle

DRUG

Bortezomib

Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.

Trial Locations (4)

69495

Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite

76038

Centre Henri Becquerel, Rouen

Unknown

Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne

Institut Gustave Roussy, Villejuif